{"title":"The Changing Landscape of Hematological <br> Malignancy Treatment","markdown":{"yaml":{"format":{"revealjs":{"touch":true,"controls":true,"transition":"fade","transition-speed":"fast","scrollable":true,"slide-number":false,"incremental":true,"multiplex":true,"chalkboard":false,"theme":["default","custom.scss"],"pointer":{"pointerSize":18,"color":"#32cd32"}}},"revealjs-plugins":["pointer"],"bibliography":"references.bib","csl":"diagnostic-microbiology-and-infectious-disease.csl","filters":["roughnotation"]},"headingText":"The Changing Landscape of Hematological <br> Malignancy Treatment","headingAttr":{"id":"","classes":[],"keyvalue":[["background-video","/images/bubbles.mp4"],["background-video-loop","true"],["background-video-muted","true"],["background-opacity","0.5"]]},"containsRefs":false,"markdown":"\n\n\n<br>\n\n### Implications for antifungal therapy\n\n<br> <br>\n\n<center>\n\nRussell E. Lewis, Pharm.D., FCCP <br> Associate Professor of Medicine, Infectious Diseases <br> Department of Molecular Medicine, University of Padua\n\n<br> <br> <br> {{< fa solid envelope size=1x >}} russelledward.lewis\\@unipd.it <br> {{< fa brands github size=1x >}} [https://github.com/Russlewisbo](https://github.com/Russlewisbo/ESCMID_2022_talk)\n\n![](University_of_Padua_seal.svg){.absolute top=\"500\" left=\"150\" width=\"150\" height=\"100\"}\n\n::: aside\nJune 26, 2024\n:::\n\n## Disclosures\n\n<br>\n\n::: nonincremental\n-   **Research funding**: Merck & Co Inc., Gilead Sciences\n-   **Speaking**: Avir, Gilead\n-   **Consultancy**: F2G, Scynexis, Basilea, Gilead Sciences, Cidara Therapeutics\n:::\n\n## The cure of leukemia through the optimist's prism {.smaller}\n\n<br>\n\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| Disease                                                                   | Current/ <br> Future therapies\\*                                                                                                                                | Survival <br> (5 year) |\n+===========================================================================+=================================================================================================================================================================+========================+\n| **Hairy cell leukemia**                                                   | Clofarabine + [gemtuzumab ozogamicin (GO)]{style=\"color:red;\"}                                                                                                  | 90%                    |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| **Acute premyelocytic leukemia**                                          | ATRA + arsenic ± [GO]{style=\"color:red;\"}                                                                                                                       | 80-90%                 |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| **AML** <br>**(core binding factor positive)**                            | FLAG-[GO]{style=\"color:red;\"} ± IDA, alloHSCT if MRD positive, if indicated, oral [AZA/HMA with venetoclax or FLT3/IDH or menin inhibitors]{style=\"color:red;\"} | 80-90%+                |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| **AML** <br>**(younger fit)**                                             | FLAG-IDA and [venetoclax]{style=\"color:red;\"}, CLIA and [venetoclax]{style=\"color:red;\"}                                                                        | 50-60%                 |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| **AML** <br> **(older, unfit, complex karyotype, T-53 mutations, MECOM)** | Low-intensity triple nucleosides (cladarabine, cytarabine and [HMAs + venetoclax; HMAs + venetoclax + targeted therapy]{style=\"color:red;\"}                     | 40-50%                 |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| **ALL \\< 60 years**                                                       | HyperCVAD + [CD19/CD20 targeted antibodies]{style=\"color:red;\"}                                                                                                 | 60-70%                 |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| **ALL \\> 60 years**                                                       | Mini-hyper CVAD+ [inotuzumab; blinatumab + ponatinib]{style=\"color:red;\"}                                                                                       | 50%                    |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| **Ph-positive ALL**                                                       | HyperCVAD + [ponatinib; blinatumab + ponatinib]{style=\"color:red;\"}                                                                                             | 70-80%?                |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n\n::: aside\n[@kantarjian2021; @kantarjian2022J] <br>\n\n\\*some therapies investigational or not licensed in Canada. Abbreviations: ALL, acute lymphoblastic leukemia; CLIA, cladribine, high-dose cytarabine, and idarubicin; FLAG-GO, fludarabine, high-dose cytarabine, and gemtuzumab ozogamicin; FLAG-GO ± IDA, fludarabine, cytarabine, granulocyte colony-stimulating factor, and gemtuzumab ozogamicin ± idarubicin; FLAG-IDA, fludarabine, high-dose cytarabine, and idarubicin; GO, gemtuzumab ozogamicin; HMA, hypomethylating agent; hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone; mini-hyper-CVD, mini-hyperfractionated cyclophosphamide, vincristine, dexamethasone; Ph, Philadelphia chromosome; SCT, stem cell transplantation. [Targeted therapies highlighted in red.]{style=\"color:red;\"}\n:::\n\n## The cure of leukemia through the optimist's prism {.smaller}\n\n<br>\n\n+---------+----------------------------------------------------------------------------------------------------------------------------+-----------------------+\n| Disease | Current/ future therapy\\*                                                                                                  | Survival <br>(5 year) |\n+=========+============================================================================================================================+=======================+\n| **CML** | [BCR-Abl1 tyrosine kinase inhibitors (imatinib, dasatinib, bosutinib, nilotunib, ponatinib)]{style=\"color:red;\"}, alloHSCT | 85-90%                |\n+---------+----------------------------------------------------------------------------------------------------------------------------+-----------------------+\n| **CLL** | [Ibrutinib, other BTKIs (acalabrutinib, zanubrutinib, pirtobrutinib)]{style=\"color:red;\"}                                  | 80-90% +              |\n+---------+----------------------------------------------------------------------------------------------------------------------------+-----------------------+\n| **MDS** | [Parenteral HMAs, oral HMAs, venetoclax, others]{style=\"color:red;\"}                                                       | 40% +                 |\n+---------+----------------------------------------------------------------------------------------------------------------------------+-----------------------+\n\n::: aside\n[@kantarjian2021; @kantarjian2022J] <br>\n\n\\*some therapies investigational or not licensed in Canada. Abbreviations: ALL, acute lymphoblastic leukemia; CLIA, cladribine, high-dose cytarabine, and idarubicin; FLAG-GO, fludarabine, high-dose cytarabine, and gemtuzumab ozogamicin; FLAG-GO ± IDA, fludarabine, cytarabine, granulocyte colony-stimulating factor, and gemtuzumab ozogamicin ± idarubicin; FLAG-IDA, fludarabine, high-dose cytarabine, and idarubicin; GO, gemtuzumab ozogamicin; HMA, hypomethylating agent; hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone; mini-hyper-CVD, mini-hyperfractionated cyclophosphamide, vincristine, dexamethasone; Ph, Philadelphia chromosome; SCT, stem cell transplantation. [Targeted therapies highlighted in red.]{style=\"color:red;\"}\n:::\n\n## Advances in allogeneic HSCT {background-image=\"images/bmt.png\" background-opacity=\"0.4\"}\n\n<br>\n\n::: nonincremental\n-   Improvements in HLA typing and matching\n-   Expanded donor pools\n-   GVHD prophylaxis and treatment (cyclophosphamide, JAK inhibitors)\n-   Refinement of reduced-intensity regimens\n-   Improved supportive care (antifungal and CMV prophylaxis)\n-   Cellular therapies for relapse prevention and treatment (DLI, CAR-T)\n-   Molecular and genomic monitoring for MRD detection\n-   [Personalized medicine (targeted therapies)]{.rn rn-type=\"highlight\"}\n:::\n\n::: aside\nCIBMTR 2023 Report Survival Rates: <br> 2016-2021 61.1% (60.6-61.5%) <br> 2011-2015 54.7% (54.2-55.2%)<br> 2006-2010 49.0% (48.5-49.6%)<br> 2001-2005 43.4% (42.7-44.1%)<br>[@penack2020]\n:::\n\n## Infectious complications after haploidentical HSCT with post-transplant cyclophosphamide\n\n![](images/cyclophos.png){fig-align=\"center\" width=\"600\"}\n\n::: aside\nMajority of infections were aspergillosis. [Fungal infection mortality rate -33%]{.rn rn-type=\"highlight\"} <br>[@amandinefayard2019]\n:::\n\n## How are newer targeted therapies... {background-image=\"bonemarrow.png\" background-opacity=\"0.5\"}\n\n<br> <br>\n\n-   Changing the epidemiology of invasive fungal diseases?\n-   Changing the risk of drug interactions and toxicity with antifungal therapy?\n-   Is there a unique role for isavuconazole?\n\n## Immune sequela of targeted therapies\n\n![](images/immune.png){fig-align=\"center\" width=\"600\"}\n\n::: aside\n[@little.etal_2021]\n:::\n\n## Unexpected consequences?\n\n<br>\n\n![](burger_NEJM.png){fig-align=\"center\" width=\"3028\"}\n\n::: aside\n[@burger2015; @chamilos2018; @herbst2015]\n:::\n\n## Ibrutinib-associated aspergillosis\n\n::: columns\n::: {.column width=\"50%\"}\n<br>\n\n<div>\n\n![](MRI.png){fig-align=\"left\"}\n\n</div>\n:::\n\n::: {.column width=\"50%\"}\n<br>\n\n<br>\n\n-   Retrospective French surveillance study identified 33 cases of aspergillosis in ibrutinib-treated patients with CLL\n-   [CNS aspergillosis in 11/27 (40%)]{style=\"color:red;\"}, most cases within 3 months of starting therapy\n-   All patients had refractory/relapsed CLL and other predisposing risk factors\n:::\n:::\n\n::: aside\n[@ghez2018; @chamilos2018]\n:::\n\n## Fungal infections in patients receiving <br> ibrutinib for lymphoid cancers\n\n::: columns\n::: {.column width=\"60%\"}\n<center>Data from MSKCC, New York</center>\n\n<div>\n\n![](ibrutinib_onset.png)\n\n</div>\n:::\n\n::: {.column width=\"40%\"}\n<br> <br>\n\n-   **In a second, retrospective study from MDACC (2014-2018):**\n    -   21 (2.5%) with proven/probable invasive mold infection\n    -   Primarily pneumonia\n    -   Mostly *Aspergillus* spp.\n    -   Risk factors: monocytopenia, ≥ 3 prior CLL therapies\n:::\n:::\n\n::: aside\n[@varughese2018; @frei2020J]\n:::\n\n## BTK drives neutrophil activation for sterilizing antifungal immunity {background-image=\"images/neutrophil.jpg\" background-opacity=\"0.2\"}\n\n<br>\n\n-   After phagocytosis of *A. fumgatus* by macrophages, BTK activates calcineurin-NFAT pathways and potentiates TNF-α signalling →\n    -   Impaired chemokine response and neutrophil recruitment\n-   Aberrant innate immune response via TREM-1 signalling pathways→ decreased respiratory burst\n-   Ibrutinib also inhibits platelet activation, granule secretion, and platelet-mediated damage of *Aspergillus*\n\n::: aside\n[@desai2024; @palmucci.etal_2023]\n\nSecond-generation BTK inhibitors acalabrutinib and zanubrutinib have since been granted FDA approval and possess greater binding selectivity and fewer off-target effects compared to ibrutinib.\n:::\n\n## Novel targeted agents-Risk of fungal infections\n\n![](images/risk.png){fig-align=\"center\" width=\"800\"}\n\n::: aside\n[@little.etal_2021]\n:::\n\n## Guideline recommendations\n\n![](Lancet%20Haematology.png){fig-align=\"center\"}\n\n![](Lancet%20_DI.png){fig-align=\"center\"}\n\n::: aside\n[@bruggemann2022; @stemler2022J]\n:::\n\n## Managing fungal infection risks with <br> novel therapies for AML\n\n### EHA consensus recommendations\n\n<br>\n\n-   Systematic review of the literature, recommendations developed using GRADE framework (4977 publications evaluated)\n-   Outcomes evaluated:\n    -   Incidence of invasive fungal disease (IFD)\n    -   Prolongation of hospitalization\n    -   Days spent in ICU/mortality associated with IFD\n    -   Potential DDIs\n-   **Evidence-based recommendations were developed for hypomethylating agents (HMAs), FLT-3 inhibitors, and venetoclax-HMA combinations**\n\n::: aside\n[@stemler2022J]\n:::\n\n## Summary of EHA recommendations-1\n\n<br>\n\n-   **Hypomethylating agent monotherapy:**\n    -   Standard use or prophylaxis not recommended\n    -   Risk of IFI increased in patients with neutropenia at onset of treatment, prior intensive chemotherapy → conditional recommendation for prophylaxis\n-   **FLT3 inhibitors (midostaurin, gilteritinib)**\n    -   Antifungal prophylaxis recommended during induction chemotherapy\n    -   Conditional recommendation for prophylaxis during consolidation in patients with risk factors (prior IFI, prolonged neutropenia)\n    -   Lack of clear medical guidance for managing drug interactions\n    -   Close monitoring favoured over empiric FLT-3 inhibitor dose reduction\n\n::: aside\n[@stemler2022J]\n:::\n\n## Summary of EHA recommendations-2\n\n<br>\n\n-   **Venetoclax**\n    -   Risk of IFI increased in patients with neutropenia at onset of treatment, prior intensive chemotherapy, or prolonged neutropenia with venetoclax\n    -   Conditional recommendation to administer prophylaxis\n    -   Careful management of drug interactions with triazoles\n\n::: aside\n[@stemler2022J]\n:::\n\n## Venetoclax dose-adjustment with triazoles\n\n<br>\n\n<center>\n\nVenetoclax + hypomethylating agents for AML;\n\nCo-administration with posaconazole ↑ venetoclax AUC 8-fold\n\n</center>\n\n<br>\n\n+------------+---------------+-----------------------------------+---------------------------------+\n| **Day**    | **Full dose** | **Moderate CYP3A4 inhibitor**[^1] | **Strong CYP3A4 inhibitor**[^2] |\n+============+===============+===================================+=================================+\n| Day 1      | 100 mg        | 50 mg                             | 10 mg                           |\n+------------+---------------+-----------------------------------+---------------------------------+\n| Day 2      | 200 mg        | 100 mg                            | 20 mg                           |\n+------------+---------------+-----------------------------------+---------------------------------+\n| Day 3      | 400 mg        | 200 mg                            | 50 mg                           |\n+------------+---------------+-----------------------------------+---------------------------------+\n| Day 4-28   | 400 mg        | 200 mg                            | 70 mg                           |\n+------------+---------------+-----------------------------------+---------------------------------+\n\n<br>\n\n::: aside\n[@stemler2022J; @bhatnagar2021J]\n:::\n\n## Triazole prophylaxis increases duration of thrombocytopenia but not neutropenia or infections with dose-adjusted venetoclax {.smaller}\n\n<br>\n\n![](venetoclax_Rausch.png){fig-align=\"center\"}\n\n::: aside\n[@rausch2019]\n:::\n\n## CYP450 Interactions: The achilles heel of triazoles\n\n<center>75-85% of patients receiving mold-active triazoles have serious drug interactions</center>\n\n![](cyp_interactions.png){fig-align=\"center\" width=\"800\"}\n\n<br>\n\n::: aside\n[@bruggemann2009a; @andes2016]\n:::\n\n## PK/PD Properties of Small Molecule Kinase Inhibitors {.smaller}\n\n<br> <br>\n\n+-----------------------+------------------------------+------------------------------+----------------------------------+--------------------------------+-------------------------------------------------------------+--------------------------------+\n| Drug                  | Venetoclax                   | Midostraurin                 | Gilteritinib                     | Ivosidenib                     | Enasidinib                                                  | Glasdegib                      |\n+=======================+==============================+==============================+==================================+================================+=============================================================+================================+\n| Specificity (targets) | BCL2                         | FLT3                         | FLT3                             | IDH1                           | IDH2                                                        | Hedgehog pathway               |\n+-----------------------+------------------------------+------------------------------+----------------------------------+--------------------------------+-------------------------------------------------------------+--------------------------------+\n| Hepatic               | [CYP3A4]{style=\"color:red;\"} | [CYP3A4]{style=\"color:red;\"} | [CYP3A4/5]{style=\"color:red;\"}   | [CYP3A4/5]{style=\"color:red;\"} | [Multiple CYP enzymes including CYP3A4]{style=\"color:red;\"} | [CYP3A4/5]{style=\"color:red;\"} |\n+-----------------------+------------------------------+------------------------------+----------------------------------+--------------------------------+-------------------------------------------------------------+--------------------------------+\n| Efflux                | Substrate of PgP, BCRP       | Not a substrate              | Substrate of PgP, not BCRP, OATP | Substrate PgP, but not BRCP    | Not a substrate of BCRP pr PgP                              | Substrate for PGP, BCRP        |\n+-----------------------+------------------------------+------------------------------+----------------------------------+--------------------------------+-------------------------------------------------------------+--------------------------------+\n\n::: aside\n[@megias-vericat2020J]\n:::\n\n## Toxicities of small-molecule kinase inhibitors\n\n![](targeted%20therapy%20toxicities.png){fig-align=\"center\" width=\"800\"}\n\n::: aside\n[@wang2020a]\n:::\n\n## Just avoid triazoles?\n\n<br>\n\n![](echinocandin.png){fig-align=\"center\" width=\"800\"}\n\n::: aside\n[@gomes2014]\n:::\n\n## <br> <br> <br> <br> <br> Is their a unique role for isavuconazole <br> vs. other triazoles? {background-image=\"bonemarrow.png\"}\n\n## Strong opinions about voriconazole\n\n![](spec.png){fig-align=\"center\" width=\"800\"}\n\n## Pharmacokinetic complexity of voriconazole\n\n<br>\n\n![](voriconazole%20PK.png){fig-align=\"center\"}\n\n::: aside\n[@trifilio2014]\n:::\n\n## Triazole toxicities\n\n<br>\n\n![](triazole%20toxicity.png){fig-align=\"center\"}\n\n::: aside\n[@Lewis2011805; @johnson2021]\n:::\n\n## \n\n<br>\n\n![](new%20title.png){fig-align=\"center\"}\n\n::: aside\n[@ostrosky-zeichner2022J]\n:::\n\n## Triazole safety\n\n<br>\n\n-   Multicenter registry of prophylaxis (n=1777) and treatment (n=816) courses\n-   Adverse effects leading to treatment discontinuation:\n    -   voriconazole (n=494) 14.2%\n    -   posaconazole (n=547) 11.3%\n    -   **isavuconazole (n=514) 3.9%**\n    -   multiple/sequenced therapy (n=454) 11.7%\n-   QTc prolongation was rare, but more frequent with voriconazole and posaconazole\n-   Severe drug interactions occurred in 4% of all treated patients\n-   IFI mortality rates were similar for all agents ranging between 1.1-1.8%\n\n::: aside\n[@ostrosky-zeichner2022J]\n:::\n\n## What makes isavuconazole <br>(isavuconazonium) unique?\n\n::: columns\n::: {.column width=\"40%\"}\n<br>\n\n<div>\n\n![](isavuconazole.png){fig-align=\"left\"}\n\n</div>\n:::\n\n::: {.column width=\"60%\"}\n<br>\n\n-   Broad spectrum of activity\n-   Prodrug IV/ oral formulations (\\> 90% bioav.)\n-   Predictable linear PK, t~1/2~=130h\n-   Less need for TDM\n-   Better safety profile than voriconazole\n    -   Less potent CYP3A4/5 inhibition\n    -   Less cutaneous, CNS, hepatic toxicities\n    -   Does not prolong QT\n:::\n:::\n\n::: aside\n[@johnson2021; @maertens2016]\n:::\n\n## QT prolongation risk with triazoles\n\n::: columns\n::: {.column width=\"40%\"}\n<br>\n\n![](QTC.png){width=\"400\"}\n:::\n\n::: {.column width=\"60%\"}\n<br>\n\n<br>\n\n-   Older triazoles inhibit human ether-a-go-go (hERG) channel, which underlies rapid K^+^ rectifier current\n-   Isavuconazole shortens cardiac QT in a dose-related manner, with no associated cardiac risk\n    -   hCav1.2 L-type Ca^++^ channels\n-   Recent analysis of FDA ERS databases confirmed lowest risk of cardiac side effects with isavuconazole\n:::\n:::\n\n::: aside\n[@keirns2017; @chen2024]\n:::\n\n## Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by *Aspergillus* and other filamentous fungi (SECURE) {.smaller}\n\n![](Secure.png){fig-align=\"center\" width=\"700\"}\n\n<br>\n\n::: aside\n[@maertens2016]\n:::\n\n## Treatment-emergent adverse effects <br> in the SECURE trial\n\n<br>\n\n-   **Overall drug-related AE (VOR-60% vs. ISA-42%, p\\<0.001)**\n    -   Hepatobiliary disorders (VOR-16% vs. ISA-9%, p=0.016)\n\n    -   Visual disturbances (VOR-27% vs. ISA-15%, p=0.002)\n\n    -   Skin or subcutaneous tissue (VOR-42% vs. ISA-33%, p=0.037)\n\n::: aside\n[@maertens2016]\n:::\n\n## Isavuconazole treatment for mucormycosis: <br> a single-arm, open-label, case-control study (VITAL)\n\n![](isavuconazole_Mucor.png){fig-align=\"center\" width=\"700\"}\n\n::: aside\n[@marty2014]\n:::\n\n## Isavuconazole drug interaction potential in HSCT\n\n<br>\n\n+--------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------+\n| Drug                           | Pharmacokinetic change                      | Initial management                                                                                                                                |\n+================================+=============================================+===================================================================================================================================================+\n| **Tacrolimus**                 | ↑ AUC 1.8-3xfold                            | 40-50% reduction in tacrolimus dose, TDM. <br>Some case series suggest no empiric dose reduction was required                                     |\n|                                |                                             |                                                                                                                                                   |\n|                                | ↑ C~max~ 1.4-2.8xfold                       |                                                                                                                                                   |\n+--------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------+\n| **Prednisone or Prednisolone** | ↑ AUC (8%) minimal                          | No dose adjustments recommended                                                                                                                   |\n+--------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------+\n| **Ruxolitinib**                | ↑AUC and C~max~ by an average of 27% and 8% | Although dose reduction is recommended for strong CYP3A4 inhibitors, no dose reduction recommended with moderate inhibitors such as isavuconazole |\n+--------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------+\n\n::: aside\n[@kufel2018; @kieu2019; @groll2017b; @ouatas2017]\n:::\n\n## Isavuconazole drug interaction potential\n\n<br>\n\n+------------------+-------------------------+----------------------------------------------------------------------------------------------+\n| Drug             | Pharmacokinetic change  | Initial management                                                                           |\n+==================+=========================+==============================================================================================+\n| **Venetoclax**   | ↑AUC 2-3.9xfold         | Dose reduction of venetoclax by 50%                                                          |\n+------------------+-------------------------+----------------------------------------------------------------------------------------------+\n| **Midostaurin**  | ↑AUC 1.44xfold higher   | Avoid strong CYP3A4 inhibitors, no dose reduction recommended for moderate CYP3A4 inhibitors |\n+------------------+-------------------------+----------------------------------------------------------------------------------------------+\n| **Gilteritinib** | ↑AUC 1.4xfold; <br>     | Avoid strong CYP3A4 inhibitors, no dose reduction recommended for moderate CYP3A4 inhibitors |\n|                  |                         |                                                                                              |\n|                  | ↑C~max~ 1.2-fold higher |                                                                                              |\n+------------------+-------------------------+----------------------------------------------------------------------------------------------+\n\n::: aside\n[@kufel2018; @kieu2019; @groll2017b; @ouatas2017]\n:::\n\n## Does TDM support claims of less potent <br> CYP3A4 inhibition?\n\n![](Menna_midostraurin.png){fig-align=\"center\"}\n\n::: aside\n[@Menna2021-mb]\n:::\n\n## \n\n![](Bose%20study.png){fig-align=\"center\"}\n\n::: aside\n[@bose2020]\n:::\n\n##  {.smaller}\n\n![](bose_study.png){fig-align=\"center\" width=\"600\"}\n\n::: aside\n[@bose2020]\n:::\n\n##{.smaller}\n\n![](bose3.png){fig-align=\"center\"}\n\n::: aside\n[@bose2020]\n:::\n\n## \n\n![](bose4.png){fig-align=\"center\"}\n\n::: aside\n[@bose2020]\n:::\n\n## Isavuconazole tolerability\n\n<br>\n\n<br>\n\n::: columns\n::: {.column width=\"50%\"}\n-   **Posaconazole experience** <br> **(previous study with tablet/IV)**\n    -   [Grade III/IV liver injury with tablet and IV formulations (9%)]{style=\"color:red;\"}\n\n    -   Primarily presenting with hyperbilirubinemia\n\n    -   Higher frequency in patients with POS serum levels \\> 1,830 ng/mL\n:::\n\n::: {.column width=\"50%\"}\n-   **Isavuconazole**\n    -   [Grade 1 transaminitis (2.7%)]{style=\"color:red;\"}\n\n    -   Grade 2 elevated T. bilirubin (1.3%)\n\n    -   No QTc elevation vs. baseline at 10 days\n:::\n\n::: fragment\n\"Isavuconazole was well tolerated and facilitated use of the most potent molecular-targeted agents in remission-induction chemotherapy with excellent short term survival and high remission rates.\"\n:::\n:::\n\n::: aside\n[@bose2020; @Tverdek2017-gh]\n:::\n\n## dd\n\n![](bose5.png){fig-align=\"center\"}\n\n<br>\n\n<br>\n\n<div>\n\n[@Young2021-jx]\n\n</div>\n\n## Jo-Anne H. Young, *Clin Infect Dis 2021*\n\n<br>\n\n<br>\n\n::: fragment\n\"This is the first antifungal prophylaxis study in this select population of patients with leukemia, specifically, those patients being treated with the BCL-2 antagonist venetoclax and fms3-like tyrosine kinase 3 (FLT3) inhibitors.\n:::\n\n<br>\n\n::: fragment\n\"Clinicians should take away from these studies the fact that many of the advanced-generation azoles can be used interchangeably in times of prophylaxis when they are needed.\"\n:::\n\n## Summary {background-image=\"bonemarrow.png\"}\n\n<br>\n\n-   **Knowledge of fungal infection risk with targeted therapy is evolving, and depends heavily on the individual patient treatment scenario** <br>\n-   **Many small molecule inhibitors are metabolised by CYP3A4/5 and have potential for QTc prolongation, making concurrent use with broad-spectrum triazoles difficult** <br>\n-   **Isavuconazole has several unique pharmacokinetic and safety advantages over older triazoles, making it an useful alternative in patients receiving targeted therapies**\n\n## Treviso, Italy\n\n![](images/treviso1.jpg){.absolute top=\"200\" left=\"0\" width=\"442\" height=\"303\"}\n\n![](images/treviso2.jpg){.absolute top=\"50\" right=\"50\" width=\"450\" height=\"250\"}\n\n![](images/prosecco3.jpg){.absolute bottom=\"0\" right=\"50\" width=\"418\" height=\"273\"}\n\n## References\n\n<br>\n\nAll figures created by R. Lewis using www.biorender.com <br> <br>\n\n[^1]: fluconazole, isavuconazole\n\n[^2]: voriconazole, posaconazole\n","srcMarkdownNoYaml":"\n\n## The Changing Landscape of Hematological <br> Malignancy Treatment {background-video=\"/images/bubbles.mp4\" background-video-loop=\"true\" background-video-muted=\"true\" background-opacity=\"0.5\"}\n\n<br>\n\n### Implications for antifungal therapy\n\n<br> <br>\n\n<center>\n\nRussell E. Lewis, Pharm.D., FCCP <br> Associate Professor of Medicine, Infectious Diseases <br> Department of Molecular Medicine, University of Padua\n\n<br> <br> <br> {{< fa solid envelope size=1x >}} russelledward.lewis\\@unipd.it <br> {{< fa brands github size=1x >}} [https://github.com/Russlewisbo](https://github.com/Russlewisbo/ESCMID_2022_talk)\n\n![](University_of_Padua_seal.svg){.absolute top=\"500\" left=\"150\" width=\"150\" height=\"100\"}\n\n::: aside\nJune 26, 2024\n:::\n\n## Disclosures\n\n<br>\n\n::: nonincremental\n-   **Research funding**: Merck & Co Inc., Gilead Sciences\n-   **Speaking**: Avir, Gilead\n-   **Consultancy**: F2G, Scynexis, Basilea, Gilead Sciences, Cidara Therapeutics\n:::\n\n## The cure of leukemia through the optimist's prism {.smaller}\n\n<br>\n\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| Disease                                                                   | Current/ <br> Future therapies\\*                                                                                                                                | Survival <br> (5 year) |\n+===========================================================================+=================================================================================================================================================================+========================+\n| **Hairy cell leukemia**                                                   | Clofarabine + [gemtuzumab ozogamicin (GO)]{style=\"color:red;\"}                                                                                                  | 90%                    |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| **Acute premyelocytic leukemia**                                          | ATRA + arsenic ± [GO]{style=\"color:red;\"}                                                                                                                       | 80-90%                 |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| **AML** <br>**(core binding factor positive)**                            | FLAG-[GO]{style=\"color:red;\"} ± IDA, alloHSCT if MRD positive, if indicated, oral [AZA/HMA with venetoclax or FLT3/IDH or menin inhibitors]{style=\"color:red;\"} | 80-90%+                |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| **AML** <br>**(younger fit)**                                             | FLAG-IDA and [venetoclax]{style=\"color:red;\"}, CLIA and [venetoclax]{style=\"color:red;\"}                                                                        | 50-60%                 |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| **AML** <br> **(older, unfit, complex karyotype, T-53 mutations, MECOM)** | Low-intensity triple nucleosides (cladarabine, cytarabine and [HMAs + venetoclax; HMAs + venetoclax + targeted therapy]{style=\"color:red;\"}                     | 40-50%                 |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| **ALL \\< 60 years**                                                       | HyperCVAD + [CD19/CD20 targeted antibodies]{style=\"color:red;\"}                                                                                                 | 60-70%                 |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| **ALL \\> 60 years**                                                       | Mini-hyper CVAD+ [inotuzumab; blinatumab + ponatinib]{style=\"color:red;\"}                                                                                       | 50%                    |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n| **Ph-positive ALL**                                                       | HyperCVAD + [ponatinib; blinatumab + ponatinib]{style=\"color:red;\"}                                                                                             | 70-80%?                |\n+---------------------------------------------------------------------------+-----------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------+\n\n::: aside\n[@kantarjian2021; @kantarjian2022J] <br>\n\n\\*some therapies investigational or not licensed in Canada. Abbreviations: ALL, acute lymphoblastic leukemia; CLIA, cladribine, high-dose cytarabine, and idarubicin; FLAG-GO, fludarabine, high-dose cytarabine, and gemtuzumab ozogamicin; FLAG-GO ± IDA, fludarabine, cytarabine, granulocyte colony-stimulating factor, and gemtuzumab ozogamicin ± idarubicin; FLAG-IDA, fludarabine, high-dose cytarabine, and idarubicin; GO, gemtuzumab ozogamicin; HMA, hypomethylating agent; hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone; mini-hyper-CVD, mini-hyperfractionated cyclophosphamide, vincristine, dexamethasone; Ph, Philadelphia chromosome; SCT, stem cell transplantation. [Targeted therapies highlighted in red.]{style=\"color:red;\"}\n:::\n\n## The cure of leukemia through the optimist's prism {.smaller}\n\n<br>\n\n+---------+----------------------------------------------------------------------------------------------------------------------------+-----------------------+\n| Disease | Current/ future therapy\\*                                                                                                  | Survival <br>(5 year) |\n+=========+============================================================================================================================+=======================+\n| **CML** | [BCR-Abl1 tyrosine kinase inhibitors (imatinib, dasatinib, bosutinib, nilotunib, ponatinib)]{style=\"color:red;\"}, alloHSCT | 85-90%                |\n+---------+----------------------------------------------------------------------------------------------------------------------------+-----------------------+\n| **CLL** | [Ibrutinib, other BTKIs (acalabrutinib, zanubrutinib, pirtobrutinib)]{style=\"color:red;\"}                                  | 80-90% +              |\n+---------+----------------------------------------------------------------------------------------------------------------------------+-----------------------+\n| **MDS** | [Parenteral HMAs, oral HMAs, venetoclax, others]{style=\"color:red;\"}                                                       | 40% +                 |\n+---------+----------------------------------------------------------------------------------------------------------------------------+-----------------------+\n\n::: aside\n[@kantarjian2021; @kantarjian2022J] <br>\n\n\\*some therapies investigational or not licensed in Canada. Abbreviations: ALL, acute lymphoblastic leukemia; CLIA, cladribine, high-dose cytarabine, and idarubicin; FLAG-GO, fludarabine, high-dose cytarabine, and gemtuzumab ozogamicin; FLAG-GO ± IDA, fludarabine, cytarabine, granulocyte colony-stimulating factor, and gemtuzumab ozogamicin ± idarubicin; FLAG-IDA, fludarabine, high-dose cytarabine, and idarubicin; GO, gemtuzumab ozogamicin; HMA, hypomethylating agent; hyper-CVAD, hyperfractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone; mini-hyper-CVD, mini-hyperfractionated cyclophosphamide, vincristine, dexamethasone; Ph, Philadelphia chromosome; SCT, stem cell transplantation. [Targeted therapies highlighted in red.]{style=\"color:red;\"}\n:::\n\n## Advances in allogeneic HSCT {background-image=\"images/bmt.png\" background-opacity=\"0.4\"}\n\n<br>\n\n::: nonincremental\n-   Improvements in HLA typing and matching\n-   Expanded donor pools\n-   GVHD prophylaxis and treatment (cyclophosphamide, JAK inhibitors)\n-   Refinement of reduced-intensity regimens\n-   Improved supportive care (antifungal and CMV prophylaxis)\n-   Cellular therapies for relapse prevention and treatment (DLI, CAR-T)\n-   Molecular and genomic monitoring for MRD detection\n-   [Personalized medicine (targeted therapies)]{.rn rn-type=\"highlight\"}\n:::\n\n::: aside\nCIBMTR 2023 Report Survival Rates: <br> 2016-2021 61.1% (60.6-61.5%) <br> 2011-2015 54.7% (54.2-55.2%)<br> 2006-2010 49.0% (48.5-49.6%)<br> 2001-2005 43.4% (42.7-44.1%)<br>[@penack2020]\n:::\n\n## Infectious complications after haploidentical HSCT with post-transplant cyclophosphamide\n\n![](images/cyclophos.png){fig-align=\"center\" width=\"600\"}\n\n::: aside\nMajority of infections were aspergillosis. [Fungal infection mortality rate -33%]{.rn rn-type=\"highlight\"} <br>[@amandinefayard2019]\n:::\n\n## How are newer targeted therapies... {background-image=\"bonemarrow.png\" background-opacity=\"0.5\"}\n\n<br> <br>\n\n-   Changing the epidemiology of invasive fungal diseases?\n-   Changing the risk of drug interactions and toxicity with antifungal therapy?\n-   Is there a unique role for isavuconazole?\n\n## Immune sequela of targeted therapies\n\n![](images/immune.png){fig-align=\"center\" width=\"600\"}\n\n::: aside\n[@little.etal_2021]\n:::\n\n## Unexpected consequences?\n\n<br>\n\n![](burger_NEJM.png){fig-align=\"center\" width=\"3028\"}\n\n::: aside\n[@burger2015; @chamilos2018; @herbst2015]\n:::\n\n## Ibrutinib-associated aspergillosis\n\n::: columns\n::: {.column width=\"50%\"}\n<br>\n\n<div>\n\n![](MRI.png){fig-align=\"left\"}\n\n</div>\n:::\n\n::: {.column width=\"50%\"}\n<br>\n\n<br>\n\n-   Retrospective French surveillance study identified 33 cases of aspergillosis in ibrutinib-treated patients with CLL\n-   [CNS aspergillosis in 11/27 (40%)]{style=\"color:red;\"}, most cases within 3 months of starting therapy\n-   All patients had refractory/relapsed CLL and other predisposing risk factors\n:::\n:::\n\n::: aside\n[@ghez2018; @chamilos2018]\n:::\n\n## Fungal infections in patients receiving <br> ibrutinib for lymphoid cancers\n\n::: columns\n::: {.column width=\"60%\"}\n<center>Data from MSKCC, New York</center>\n\n<div>\n\n![](ibrutinib_onset.png)\n\n</div>\n:::\n\n::: {.column width=\"40%\"}\n<br> <br>\n\n-   **In a second, retrospective study from MDACC (2014-2018):**\n    -   21 (2.5%) with proven/probable invasive mold infection\n    -   Primarily pneumonia\n    -   Mostly *Aspergillus* spp.\n    -   Risk factors: monocytopenia, ≥ 3 prior CLL therapies\n:::\n:::\n\n::: aside\n[@varughese2018; @frei2020J]\n:::\n\n## BTK drives neutrophil activation for sterilizing antifungal immunity {background-image=\"images/neutrophil.jpg\" background-opacity=\"0.2\"}\n\n<br>\n\n-   After phagocytosis of *A. fumgatus* by macrophages, BTK activates calcineurin-NFAT pathways and potentiates TNF-α signalling →\n    -   Impaired chemokine response and neutrophil recruitment\n-   Aberrant innate immune response via TREM-1 signalling pathways→ decreased respiratory burst\n-   Ibrutinib also inhibits platelet activation, granule secretion, and platelet-mediated damage of *Aspergillus*\n\n::: aside\n[@desai2024; @palmucci.etal_2023]\n\nSecond-generation BTK inhibitors acalabrutinib and zanubrutinib have since been granted FDA approval and possess greater binding selectivity and fewer off-target effects compared to ibrutinib.\n:::\n\n## Novel targeted agents-Risk of fungal infections\n\n![](images/risk.png){fig-align=\"center\" width=\"800\"}\n\n::: aside\n[@little.etal_2021]\n:::\n\n## Guideline recommendations\n\n![](Lancet%20Haematology.png){fig-align=\"center\"}\n\n![](Lancet%20_DI.png){fig-align=\"center\"}\n\n::: aside\n[@bruggemann2022; @stemler2022J]\n:::\n\n## Managing fungal infection risks with <br> novel therapies for AML\n\n### EHA consensus recommendations\n\n<br>\n\n-   Systematic review of the literature, recommendations developed using GRADE framework (4977 publications evaluated)\n-   Outcomes evaluated:\n    -   Incidence of invasive fungal disease (IFD)\n    -   Prolongation of hospitalization\n    -   Days spent in ICU/mortality associated with IFD\n    -   Potential DDIs\n-   **Evidence-based recommendations were developed for hypomethylating agents (HMAs), FLT-3 inhibitors, and venetoclax-HMA combinations**\n\n::: aside\n[@stemler2022J]\n:::\n\n## Summary of EHA recommendations-1\n\n<br>\n\n-   **Hypomethylating agent monotherapy:**\n    -   Standard use or prophylaxis not recommended\n    -   Risk of IFI increased in patients with neutropenia at onset of treatment, prior intensive chemotherapy → conditional recommendation for prophylaxis\n-   **FLT3 inhibitors (midostaurin, gilteritinib)**\n    -   Antifungal prophylaxis recommended during induction chemotherapy\n    -   Conditional recommendation for prophylaxis during consolidation in patients with risk factors (prior IFI, prolonged neutropenia)\n    -   Lack of clear medical guidance for managing drug interactions\n    -   Close monitoring favoured over empiric FLT-3 inhibitor dose reduction\n\n::: aside\n[@stemler2022J]\n:::\n\n## Summary of EHA recommendations-2\n\n<br>\n\n-   **Venetoclax**\n    -   Risk of IFI increased in patients with neutropenia at onset of treatment, prior intensive chemotherapy, or prolonged neutropenia with venetoclax\n    -   Conditional recommendation to administer prophylaxis\n    -   Careful management of drug interactions with triazoles\n\n::: aside\n[@stemler2022J]\n:::\n\n## Venetoclax dose-adjustment with triazoles\n\n<br>\n\n<center>\n\nVenetoclax + hypomethylating agents for AML;\n\nCo-administration with posaconazole ↑ venetoclax AUC 8-fold\n\n</center>\n\n<br>\n\n+------------+---------------+-----------------------------------+---------------------------------+\n| **Day**    | **Full dose** | **Moderate CYP3A4 inhibitor**[^1] | **Strong CYP3A4 inhibitor**[^2] |\n+============+===============+===================================+=================================+\n| Day 1      | 100 mg        | 50 mg                             | 10 mg                           |\n+------------+---------------+-----------------------------------+---------------------------------+\n| Day 2      | 200 mg        | 100 mg                            | 20 mg                           |\n+------------+---------------+-----------------------------------+---------------------------------+\n| Day 3      | 400 mg        | 200 mg                            | 50 mg                           |\n+------------+---------------+-----------------------------------+---------------------------------+\n| Day 4-28   | 400 mg        | 200 mg                            | 70 mg                           |\n+------------+---------------+-----------------------------------+---------------------------------+\n\n<br>\n\n::: aside\n[@stemler2022J; @bhatnagar2021J]\n:::\n\n## Triazole prophylaxis increases duration of thrombocytopenia but not neutropenia or infections with dose-adjusted venetoclax {.smaller}\n\n<br>\n\n![](venetoclax_Rausch.png){fig-align=\"center\"}\n\n::: aside\n[@rausch2019]\n:::\n\n## CYP450 Interactions: The achilles heel of triazoles\n\n<center>75-85% of patients receiving mold-active triazoles have serious drug interactions</center>\n\n![](cyp_interactions.png){fig-align=\"center\" width=\"800\"}\n\n<br>\n\n::: aside\n[@bruggemann2009a; @andes2016]\n:::\n\n## PK/PD Properties of Small Molecule Kinase Inhibitors {.smaller}\n\n<br> <br>\n\n+-----------------------+------------------------------+------------------------------+----------------------------------+--------------------------------+-------------------------------------------------------------+--------------------------------+\n| Drug                  | Venetoclax                   | Midostraurin                 | Gilteritinib                     | Ivosidenib                     | Enasidinib                                                  | Glasdegib                      |\n+=======================+==============================+==============================+==================================+================================+=============================================================+================================+\n| Specificity (targets) | BCL2                         | FLT3                         | FLT3                             | IDH1                           | IDH2                                                        | Hedgehog pathway               |\n+-----------------------+------------------------------+------------------------------+----------------------------------+--------------------------------+-------------------------------------------------------------+--------------------------------+\n| Hepatic               | [CYP3A4]{style=\"color:red;\"} | [CYP3A4]{style=\"color:red;\"} | [CYP3A4/5]{style=\"color:red;\"}   | [CYP3A4/5]{style=\"color:red;\"} | [Multiple CYP enzymes including CYP3A4]{style=\"color:red;\"} | [CYP3A4/5]{style=\"color:red;\"} |\n+-----------------------+------------------------------+------------------------------+----------------------------------+--------------------------------+-------------------------------------------------------------+--------------------------------+\n| Efflux                | Substrate of PgP, BCRP       | Not a substrate              | Substrate of PgP, not BCRP, OATP | Substrate PgP, but not BRCP    | Not a substrate of BCRP pr PgP                              | Substrate for PGP, BCRP        |\n+-----------------------+------------------------------+------------------------------+----------------------------------+--------------------------------+-------------------------------------------------------------+--------------------------------+\n\n::: aside\n[@megias-vericat2020J]\n:::\n\n## Toxicities of small-molecule kinase inhibitors\n\n![](targeted%20therapy%20toxicities.png){fig-align=\"center\" width=\"800\"}\n\n::: aside\n[@wang2020a]\n:::\n\n## Just avoid triazoles?\n\n<br>\n\n![](echinocandin.png){fig-align=\"center\" width=\"800\"}\n\n::: aside\n[@gomes2014]\n:::\n\n## <br> <br> <br> <br> <br> Is their a unique role for isavuconazole <br> vs. other triazoles? {background-image=\"bonemarrow.png\"}\n\n## Strong opinions about voriconazole\n\n![](spec.png){fig-align=\"center\" width=\"800\"}\n\n## Pharmacokinetic complexity of voriconazole\n\n<br>\n\n![](voriconazole%20PK.png){fig-align=\"center\"}\n\n::: aside\n[@trifilio2014]\n:::\n\n## Triazole toxicities\n\n<br>\n\n![](triazole%20toxicity.png){fig-align=\"center\"}\n\n::: aside\n[@Lewis2011805; @johnson2021]\n:::\n\n## \n\n<br>\n\n![](new%20title.png){fig-align=\"center\"}\n\n::: aside\n[@ostrosky-zeichner2022J]\n:::\n\n## Triazole safety\n\n<br>\n\n-   Multicenter registry of prophylaxis (n=1777) and treatment (n=816) courses\n-   Adverse effects leading to treatment discontinuation:\n    -   voriconazole (n=494) 14.2%\n    -   posaconazole (n=547) 11.3%\n    -   **isavuconazole (n=514) 3.9%**\n    -   multiple/sequenced therapy (n=454) 11.7%\n-   QTc prolongation was rare, but more frequent with voriconazole and posaconazole\n-   Severe drug interactions occurred in 4% of all treated patients\n-   IFI mortality rates were similar for all agents ranging between 1.1-1.8%\n\n::: aside\n[@ostrosky-zeichner2022J]\n:::\n\n## What makes isavuconazole <br>(isavuconazonium) unique?\n\n::: columns\n::: {.column width=\"40%\"}\n<br>\n\n<div>\n\n![](isavuconazole.png){fig-align=\"left\"}\n\n</div>\n:::\n\n::: {.column width=\"60%\"}\n<br>\n\n-   Broad spectrum of activity\n-   Prodrug IV/ oral formulations (\\> 90% bioav.)\n-   Predictable linear PK, t~1/2~=130h\n-   Less need for TDM\n-   Better safety profile than voriconazole\n    -   Less potent CYP3A4/5 inhibition\n    -   Less cutaneous, CNS, hepatic toxicities\n    -   Does not prolong QT\n:::\n:::\n\n::: aside\n[@johnson2021; @maertens2016]\n:::\n\n## QT prolongation risk with triazoles\n\n::: columns\n::: {.column width=\"40%\"}\n<br>\n\n![](QTC.png){width=\"400\"}\n:::\n\n::: {.column width=\"60%\"}\n<br>\n\n<br>\n\n-   Older triazoles inhibit human ether-a-go-go (hERG) channel, which underlies rapid K^+^ rectifier current\n-   Isavuconazole shortens cardiac QT in a dose-related manner, with no associated cardiac risk\n    -   hCav1.2 L-type Ca^++^ channels\n-   Recent analysis of FDA ERS databases confirmed lowest risk of cardiac side effects with isavuconazole\n:::\n:::\n\n::: aside\n[@keirns2017; @chen2024]\n:::\n\n## Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by *Aspergillus* and other filamentous fungi (SECURE) {.smaller}\n\n![](Secure.png){fig-align=\"center\" width=\"700\"}\n\n<br>\n\n::: aside\n[@maertens2016]\n:::\n\n## Treatment-emergent adverse effects <br> in the SECURE trial\n\n<br>\n\n-   **Overall drug-related AE (VOR-60% vs. ISA-42%, p\\<0.001)**\n    -   Hepatobiliary disorders (VOR-16% vs. ISA-9%, p=0.016)\n\n    -   Visual disturbances (VOR-27% vs. ISA-15%, p=0.002)\n\n    -   Skin or subcutaneous tissue (VOR-42% vs. ISA-33%, p=0.037)\n\n::: aside\n[@maertens2016]\n:::\n\n## Isavuconazole treatment for mucormycosis: <br> a single-arm, open-label, case-control study (VITAL)\n\n![](isavuconazole_Mucor.png){fig-align=\"center\" width=\"700\"}\n\n::: aside\n[@marty2014]\n:::\n\n## Isavuconazole drug interaction potential in HSCT\n\n<br>\n\n+--------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------+\n| Drug                           | Pharmacokinetic change                      | Initial management                                                                                                                                |\n+================================+=============================================+===================================================================================================================================================+\n| **Tacrolimus**                 | ↑ AUC 1.8-3xfold                            | 40-50% reduction in tacrolimus dose, TDM. <br>Some case series suggest no empiric dose reduction was required                                     |\n|                                |                                             |                                                                                                                                                   |\n|                                | ↑ C~max~ 1.4-2.8xfold                       |                                                                                                                                                   |\n+--------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------+\n| **Prednisone or Prednisolone** | ↑ AUC (8%) minimal                          | No dose adjustments recommended                                                                                                                   |\n+--------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------+\n| **Ruxolitinib**                | ↑AUC and C~max~ by an average of 27% and 8% | Although dose reduction is recommended for strong CYP3A4 inhibitors, no dose reduction recommended with moderate inhibitors such as isavuconazole |\n+--------------------------------+---------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------------------+\n\n::: aside\n[@kufel2018; @kieu2019; @groll2017b; @ouatas2017]\n:::\n\n## Isavuconazole drug interaction potential\n\n<br>\n\n+------------------+-------------------------+----------------------------------------------------------------------------------------------+\n| Drug             | Pharmacokinetic change  | Initial management                                                                           |\n+==================+=========================+==============================================================================================+\n| **Venetoclax**   | ↑AUC 2-3.9xfold         | Dose reduction of venetoclax by 50%                                                          |\n+------------------+-------------------------+----------------------------------------------------------------------------------------------+\n| **Midostaurin**  | ↑AUC 1.44xfold higher   | Avoid strong CYP3A4 inhibitors, no dose reduction recommended for moderate CYP3A4 inhibitors |\n+------------------+-------------------------+----------------------------------------------------------------------------------------------+\n| **Gilteritinib** | ↑AUC 1.4xfold; <br>     | Avoid strong CYP3A4 inhibitors, no dose reduction recommended for moderate CYP3A4 inhibitors |\n|                  |                         |                                                                                              |\n|                  | ↑C~max~ 1.2-fold higher |                                                                                              |\n+------------------+-------------------------+----------------------------------------------------------------------------------------------+\n\n::: aside\n[@kufel2018; @kieu2019; @groll2017b; @ouatas2017]\n:::\n\n## Does TDM support claims of less potent <br> CYP3A4 inhibition?\n\n![](Menna_midostraurin.png){fig-align=\"center\"}\n\n::: aside\n[@Menna2021-mb]\n:::\n\n## \n\n![](Bose%20study.png){fig-align=\"center\"}\n\n::: aside\n[@bose2020]\n:::\n\n##  {.smaller}\n\n![](bose_study.png){fig-align=\"center\" width=\"600\"}\n\n::: aside\n[@bose2020]\n:::\n\n##{.smaller}\n\n![](bose3.png){fig-align=\"center\"}\n\n::: aside\n[@bose2020]\n:::\n\n## \n\n![](bose4.png){fig-align=\"center\"}\n\n::: aside\n[@bose2020]\n:::\n\n## Isavuconazole tolerability\n\n<br>\n\n<br>\n\n::: columns\n::: {.column width=\"50%\"}\n-   **Posaconazole experience** <br> **(previous study with tablet/IV)**\n    -   [Grade III/IV liver injury with tablet and IV formulations (9%)]{style=\"color:red;\"}\n\n    -   Primarily presenting with hyperbilirubinemia\n\n    -   Higher frequency in patients with POS serum levels \\> 1,830 ng/mL\n:::\n\n::: {.column width=\"50%\"}\n-   **Isavuconazole**\n    -   [Grade 1 transaminitis (2.7%)]{style=\"color:red;\"}\n\n    -   Grade 2 elevated T. bilirubin (1.3%)\n\n    -   No QTc elevation vs. baseline at 10 days\n:::\n\n::: fragment\n\"Isavuconazole was well tolerated and facilitated use of the most potent molecular-targeted agents in remission-induction chemotherapy with excellent short term survival and high remission rates.\"\n:::\n:::\n\n::: aside\n[@bose2020; @Tverdek2017-gh]\n:::\n\n## dd\n\n![](bose5.png){fig-align=\"center\"}\n\n<br>\n\n<br>\n\n<div>\n\n[@Young2021-jx]\n\n</div>\n\n## Jo-Anne H. Young, *Clin Infect Dis 2021*\n\n<br>\n\n<br>\n\n::: fragment\n\"This is the first antifungal prophylaxis study in this select population of patients with leukemia, specifically, those patients being treated with the BCL-2 antagonist venetoclax and fms3-like tyrosine kinase 3 (FLT3) inhibitors.\n:::\n\n<br>\n\n::: fragment\n\"Clinicians should take away from these studies the fact that many of the advanced-generation azoles can be used interchangeably in times of prophylaxis when they are needed.\"\n:::\n\n## Summary {background-image=\"bonemarrow.png\"}\n\n<br>\n\n-   **Knowledge of fungal infection risk with targeted therapy is evolving, and depends heavily on the individual patient treatment scenario** <br>\n-   **Many small molecule inhibitors are metabolised by CYP3A4/5 and have potential for QTc prolongation, making concurrent use with broad-spectrum triazoles difficult** <br>\n-   **Isavuconazole has several unique pharmacokinetic and safety advantages over older triazoles, making it an useful alternative in patients receiving targeted therapies**\n\n## Treviso, Italy\n\n![](images/treviso1.jpg){.absolute top=\"200\" left=\"0\" width=\"442\" height=\"303\"}\n\n![](images/treviso2.jpg){.absolute top=\"50\" right=\"50\" width=\"450\" height=\"250\"}\n\n![](images/prosecco3.jpg){.absolute bottom=\"0\" right=\"50\" width=\"418\" height=\"273\"}\n\n## References\n\n<br>\n\nAll figures created by R. Lewis using www.biorender.com <br> <br>\n\n[^1]: fluconazole, isavuconazole\n\n[^2]: voriconazole, posaconazole\n"},"formats":{"revealjs":{"identifier":{"display-name":"RevealJS","target-format":"revealjs","base-format":"revealjs"},"execute":{"fig-width":10,"fig-height":5,"fig-format":"retina","fig-dpi":96,"df-print":"default","error":false,"eval":true,"cache":null,"freeze":false,"echo":false,"output":true,"warning":false,"include":true,"keep-md":false,"keep-ipynb":false,"ipynb":null,"enabled":null,"daemon":null,"daemon-restart":false,"debug":false,"ipynb-filters":[],"ipynb-shell-interactivity":null,"plotly-connected":true,"engine":"markdown"},"render":{"keep-tex":false,"keep-typ":false,"keep-source":false,"keep-hidden":false,"prefer-html":false,"output-divs":true,"output-ext":"html","fig-align":"default","fig-pos":null,"fig-env":null,"code-fold":"none","code-overflow":"scroll","code-link":false,"code-line-numbers":true,"code-tools":false,"tbl-colwidths":"auto","merge-includes":true,"inline-includes":false,"preserve-yaml":false,"latex-auto-mk":true,"latex-auto-install":true,"latex-clean":true,"latex-min-runs":1,"latex-max-runs":10,"latex-makeindex":"makeindex","latex-makeindex-opts":[],"latex-tlmgr-opts":[],"latex-input-paths":[],"latex-output-dir":null,"link-external-icon":false,"link-external-newwindow":false,"self-contained-math":false,"format-resources":[]},"pandoc":{"standalone":true,"wrap":"none","default-image-extension":"png","html-math-method":{"method":"mathjax","url":"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.0/MathJax.js?config=TeX-AMS_HTML-full"},"slide-level":2,"to":"revealjs","filters":["roughnotation"],"incremental":true,"output-file":"avir talk.html"},"language":{"toc-title-document":"Table of contents","toc-title-website":"On this page","related-formats-title":"Other Formats","related-notebooks-title":"Notebooks","source-notebooks-prefix":"Source","other-links-title":"Other Links","code-links-title":"Code Links","launch-dev-container-title":"Launch Dev Container","launch-binder-title":"Launch Binder","article-notebook-label":"Article Notebook","notebook-preview-download":"Download Notebook","notebook-preview-download-src":"Download Source","notebook-preview-back":"Back to Article","manuscript-meca-bundle":"MECA Bundle","section-title-abstract":"Abstract","section-title-appendices":"Appendices","section-title-footnotes":"Footnotes","section-title-references":"References","section-title-reuse":"Reuse","section-title-copyright":"Copyright","section-title-citation":"Citation","appendix-attribution-cite-as":"For attribution, please cite this work as:","appendix-attribution-bibtex":"BibTeX citation:","title-block-author-single":"Author","title-block-author-plural":"Authors","title-block-affiliation-single":"Affiliation","title-block-affiliation-plural":"Affiliations","title-block-published":"Published","title-block-modified":"Modified","title-block-keywords":"Keywords","callout-tip-title":"Tip","callout-note-title":"Note","callout-warning-title":"Warning","callout-important-title":"Important","callout-caution-title":"Caution","code-summary":"Code","code-tools-menu-caption":"Code","code-tools-show-all-code":"Show All Code","code-tools-hide-all-code":"Hide All Code","code-tools-view-source":"View Source","code-tools-source-code":"Source Code","tools-share":"Share","tools-download":"Download","code-line":"Line","code-lines":"Lines","copy-button-tooltip":"Copy to Clipboard","copy-button-tooltip-success":"Copied!","repo-action-links-edit":"Edit this page","repo-action-links-source":"View source","repo-action-links-issue":"Report an issue","back-to-top":"Back to top","search-no-results-text":"No results","search-matching-documents-text":"matching documents","search-copy-link-title":"Copy link to search","search-hide-matches-text":"Hide additional matches","search-more-match-text":"more match in this document","search-more-matches-text":"more matches in this document","search-clear-button-title":"Clear","search-text-placeholder":"","search-detached-cancel-button-title":"Cancel","search-submit-button-title":"Submit","search-label":"Search","toggle-section":"Toggle section","toggle-sidebar":"Toggle sidebar navigation","toggle-dark-mode":"Toggle dark mode","toggle-reader-mode":"Toggle reader mode","toggle-navigation":"Toggle navigation","crossref-fig-title":"Figure","crossref-tbl-title":"Table","crossref-lst-title":"Listing","crossref-thm-title":"Theorem","crossref-lem-title":"Lemma","crossref-cor-title":"Corollary","crossref-prp-title":"Proposition","crossref-cnj-title":"Conjecture","crossref-def-title":"Definition","crossref-exm-title":"Example","crossref-exr-title":"Exercise","crossref-ch-prefix":"Chapter","crossref-apx-prefix":"Appendix","crossref-sec-prefix":"Section","crossref-eq-prefix":"Equation","crossref-lof-title":"List of Figures","crossref-lot-title":"List of Tables","crossref-lol-title":"List of Listings","environment-proof-title":"Proof","environment-remark-title":"Remark","environment-solution-title":"Solution","listing-page-order-by":"Order By","listing-page-order-by-default":"Default","listing-page-order-by-date-asc":"Oldest","listing-page-order-by-date-desc":"Newest","listing-page-order-by-number-desc":"High to Low","listing-page-order-by-number-asc":"Low to High","listing-page-field-date":"Date","listing-page-field-title":"Title","listing-page-field-description":"Description","listing-page-field-author":"Author","listing-page-field-filename":"File Name","listing-page-field-filemodified":"Modified","listing-page-field-subtitle":"Subtitle","listing-page-field-readingtime":"Reading Time","listing-page-field-wordcount":"Word Count","listing-page-field-categories":"Categories","listing-page-minutes-compact":"{0} min","listing-page-category-all":"All","listing-page-no-matches":"No matching items","listing-page-words":"{0} words"},"metadata":{"lang":"en","fig-responsive":false,"quarto-version":"1.4.552","auto-stretch":true,"editor":"visual","revealjs-plugins":["pointer"],"bibliography":["references.bib"],"csl":"diagnostic-microbiology-and-infectious-disease.csl","touch":true,"controls":true,"transition":"fade","transitionSpeed":"fast","scrollable":true,"slideNumber":false,"multiplex":true,"chalkboard":false,"theme":["default","custom.scss"],"pointer":{"pointerSize":18,"color":"#32cd32"}}}},"projectFormats":[]}